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The application of liposomes to assist drug delivery has already had a major impact
on many biomedical areas. They have been shown to be beneficial for stabilizing
therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and
improving biodistribution of compounds to target sites in vivo. This enables effective
delivery of encapsulated compounds to target sites while minimizing systemic toxicity.
Liposomes present as an attractive delivery system due to their flexible physicochemical
and biophysical properties, which allow easy manipulation to address different delivery
considerations. Despite considerable research in the last 50 years and the plethora
of positive results in preclinical studies, the clinical translation of liposome assisted
drug delivery platforms has progressed incrementally. In this review, we will discuss
the advances in liposome assisted drug delivery, biological challenges that still remain,
and current clinical and experimental use of liposomes for biomedical applications. The
translational obstacles of liposomal technology will also be presented.
Keywords: liposomes, drug delivery, lipid-based drug delivery system, nanotechnology, biological challenges,
translation, accelerated blood clearance, complement activation–related pseudoallergy
INTRODUCTION
Liposomes are the most common and well-investigated nanocarriers for targeted drug delivery.
They have improved therapies for a range of biomedical applications by stabilizing therapeutic
compounds, overcoming obstacles to cellular and tissue uptake, and improving biodistribution
of compounds to target sites in vivo (Koning and Storm, 2003; Metselaar and Storm, 2005; Ding
et al., 2006; Hua and Wu, 2013). Liposomes are defined as phospholipid vesicles consisting of
one or more concentric lipid bilayers enclosing discrete aqueous spaces. The unique ability of
liposomal systems to entrap both lipophilic and hydrophilic compounds enables a diverse range
of drugs to be encapsulated by these vesicles. Hydrophobic molecules are inserted into the bilayer
membrane, and hydrophilic molecules can be entrapped in the aqueous center (Koning and Storm,
2003; Metselaar and Storm, 2005; Ding et al., 2006; Hua and Wu, 2013; Figure 1). Furthermore,
the large aqueous center and biocompatible lipid exterior permits the delivery of a variety of
macromolecules, such as DNA, proteins and imaging agents (Ulrich, 2002; Monteiro et al., 2014).
As a drug delivery system, liposomes offer several advantages including biocompatibility, capacity
for self-assembly, ability to carry large drug payloads, and a wide range of physicochemical
and biophysical properties that can be modified to control their biological characteristics
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FIGURE 1 | Schematic representation of the different types of liposomal drug delivery systems. (A) Conventional liposome—Liposomes consist of a lipid
bilayer that can be composed of cationic, anionic, or neutral (phospho)lipids and cholesterol, which encloses an aqueous core. Both the lipid bilayer and the aqueous
space can incorporate hydrophobic or hydrophilic compounds, respectively. (B) PEGylated liposome—Liposome characteristics and behavior in vivo can be modified
by addition of a hydrophilic polymer coating, polyethylene glycol (PEG), to the liposome surface to confer steric stabilization. (C) Ligand-targeted liposome—Liposomes
can be used for specific targeting by attaching ligands (e.g., antibodies, peptides, and carbohydrates) to its surface or to the terminal end of the attached PEG chains.
(D) Theranostic liposome—A single system consist of a nanoparticle, a targeting element, an imaging component, and a therapeutic component.
(Koning and Storm, 2003; Metselaar and Storm, 2005; Ding
et al., 2006; Hua and Wu, 2013). Liposomal formulations
are characterized by properties such as particle size, charge,
number of lamellae, lipid composition, and surface modification
with polymers and ligands—these all govern their stability
in vitro and in vivo (Hua and Wu, 2013; Monteiro et al.,
2014). Encapsulation within liposomes protects compounds from
early inactivation, degradation and dilution in the circulation
(Ulrich, 2002). Liposomes are generally considered to be
pharmacologically inactive with minimal toxicity, as they tend
to be composed of natural phospholipids (Koning and Storm,
2003; Metselaar and Storm, 2005; Ding et al., 2006; Hua
and Wu, 2013); however increasing number of studies have
shown that liposomes are not as immunologically inert as once
suggested (Szebeni and Moghimi, 2009). Despite the success
of liposomal formulations in vivo, their translation into the
clinic has progressed incrementally. This review will address
the advances, biological challenges, biomedical applications, and
translational obstacles of liposomal technology.
TYPES OF LIPOSOMAL DRUG DELIVERY
PLATFORMS
In general, there are four key types of liposomal delivery
systems—conventional liposomes, sterically-stabilized
liposomes, ligand-targeted liposomes, and a combination of
the above (Figure 1). Conventional liposomes were the first
generation of liposomes to be developed. They consist of a
lipid bilayer that can be composed of cationic, anionic, or
neutral (phospho)lipids and cholesterol, which encloses an
aqueous volume (Figure 1). Research on the clinical potential of
conventional liposomes began in the 1980s, whereby liposomal
delivery proved useful for improving the therapeutic index of
encapsulated drugs, such as doxorubicin and amphotericin
(Gabizon et al., 1982; Koning and Storm, 2003; Metselaar
and Storm, 2005; Ding et al., 2006; Hua and Wu, 2013).
Conventional liposomal formulations reduced the toxicity of
compounds in vivo, through modifying pharmacokinetics and
biodistribution to enhance drug delivery to diseased tissue in
comparison to free drug. However, the delivery system was prone
to rapid elimination from the bloodstream, therefore limiting
its therapeutic efficacy (Gabizon et al., 1991, 1994). This rapid
clearance was due to opsonization of plasma components and
uptake by fixed macrophages of the reticuloendothelial system
(RES), mainly in the liver and spleen (Hua and Wu, 2013).
To improve liposome stability and enhance their circulation
times in the blood, sterically-stabilized liposomes were
introduced. The hydrophilic polymer, polyethylene glycol
(PEG), has been shown to be the optimal choice for obtaining
sterically-stabilized liposomes (Figure 1). The establishment
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of a steric barrier improves the efficacy of encapsulated agents
by reducing in vivo opsonization with serum components, and
the rapid recognition and uptake by the RES. This not only
reduces the elimination of drugs by prolonging blood circulation
and providing accumulation at pathological sites, but also
attenuates side effects (Torchilin et al., 1992; Northfelt et al.,
1996; Ishida et al., 2001b). Steric stabilization strongly influences
the pharmacokinetics of liposomes (Gabizon et al., 1993), with
reported half-lives varying from 2 to 24 h in rodents (mice and
rats) and as high as 45 h in humans, depending on the particle
size and the characteristics of the coating polymer (Allen, 1994;
Moghimi and Szebeni, 2003). While coating liposomes with PEG
results in prolonged circulation times, there can be an offsetting
reduction in the ability to interact with the intended targets
(Willis and Forssen, 1998; Ulrich, 2002).
Ligand-targeted liposomes offer a vast potential for site-
specific delivery of drugs to designated cell types or organs
in vivo, which selectively express or over-express specific
ligands (e.g., receptors or cell adhesion molecules) at the site
of disease (Willis and Forssen, 1998; Hua, 2013). Many types
of ligands are available, such as antibodies, peptides/proteins
and carbohydrates (Figure 1). The coupling of antibodies,
particularly monoclonal antibodies, to create immunoliposomes
represents one of the more versatile ligands that can be
affixed to liposome surfaces (Bendas, 2001; Puri et al., 2009).
One of the advantages of using monoclonal antibodies is
their stability and higher binding avidity because of the
presence of two binding sites on the molecule. Since lipid
assemblies are usually dynamic structures, surface-coupled
ligands have a high motional freedom to position themselves
for optimal substrate-interactions (Willis and Forssen, 1998).
The limited in vivo performance of immunoliposomes, due
to poor pharmacokinetics and immunogenicity, has been a
major hurdle to achieving their potential as effective site-
specific drug carriers (Puri et al., 2009). Therefore, newer
generation of liposomes have utilized a combination of the
above design platforms to further improve liposomal targeting
and associated drug delivery (discussed in Experimental
use of liposomes for biomedical applications). For example,
integrating target-specific binding of immunoliposomes
with the steric stabilization of PEG (thereby creating long-
circulating immunoliposomes) has significantly improved the
pharmacokinetics of immunoliposomes (Maruyama, 2002).
Overall as a drug delivery platform, liposomes offer a dynamic
and adaptable technology for enhancing the systemic efficacy of
therapeutics in various diseases.
BIOLOGICAL CHALLENGES FACING
LIPOSOMAL DRUG DELIVERY SYSTEMS
As with any foreign particle that enters the body, liposomes
encounter multiple defense systems aimed at recognition,
neutralization, and elimination of invading substances. These
defenses include the RES, opsonization, and immunogenicity
(Willis and Forssen, 1998). While these obstacles must be
circumvented for optimal liposome function, other factors such
as the enhanced permeability and retention (EPR) effect can be
exploited to enhance drug delivery (Sawant and Torchilin, 2012).
The Reticuloendothelial System (RES) and
Liposome Clearance
The RES is the main site of liposome accumulation following
their systemic administration (Poste et al., 1976; Senior, 1987).
Primary organs associated with the RES include the liver, spleen,
kidney, lungs, bone marrow, and lymph nodes (Senior, 1987).
The liver exhibits the largest capacity for liposomal uptake
followed by the spleen, which can accumulate liposomes up to
10-fold higher than other RES organs (Chrai et al., 2002). The
ability of the RES to sequester liposomes from the circulation
is attributed to fenestrations in their microvasculature. Pore
diameters in these capillaries can range from 100 to 800 nm,
which is large enough for the extravasation and subsequent
removal of most drug-loaded liposomes (50–1000 nm in size)
(Sapra and Allen, 2003). Liposomes are cleared in the RES
by resident macrophages via direct interactions with the
phagocytic cells (Chrai et al., 2002). Uptake of liposomes by
the RES is typically secondary to vesicle opsonization—that is,
the adsorption of plasma proteins such as immunoglobulin,
fibronectin, lipoproteins, and/or complement proteins onto the
phospholipid membrane (Ishida et al., 2001a; Chrai et al., 2002).
However, in vitro studies have demonstrated that liposomal
clearance via macrophages can also occur in the absence of
plasma proteins (Chrai et al., 2002).
The cells of the RES are also part of the innate immune system,
which has raised the question of whether macrophage saturation
by liposomes leads to immunosuppression and increases the
risk of infections. Excessive liposome deposition in macrophages
may impair their phagocytic capacity or modulate other cellular
functions; however there have been no reports to date of clinically
significant immune suppression at therapeutic doses of non-
cytotoxic liposomes (Szebeni and Barenholz, 2009; Szebeni and
Moghimi, 2009). The situation is different with anti-cancer
liposomes that contain cytotoxic drugs, which are capable of
inducing macrophage destruction. Although clinically important
blockade of macrophage function in humans have not yet been
demonstrated, there have been indirect signs that suggest the
possibility of some immune suppression (Szebeni and Barenholz,
2009; Szebeni and Moghimi, 2009). For example, administration
of pegylated liposomal doxorubicin (PLD) (Doxil R©) in mice
showed a dose-dependent clearance saturation effect due to
partial blockade of the RES in the liver. This effect was not
present after administration of a similar free doxorubicin dose or
phospholipid dose in drug-free liposomes (Gabizon et al., 2002).
In addition, administration of Doxil R© in mice was reported to
interfere with the clearance of bacteria from the blood, which
was suggested to be due to macrophage suppression (Storm et al.,
1998; Szebeni and Barenholz, 2009).
Conjugation of PEG polymers to the liposomal membrane is
a key strategy for improving circulation times and preventing
removal by the RES through steric stabilization (Oku andNamba,
1994; Ishida et al., 2001a). PEGylation creates a local surface
concentration of highly hydrated groups, which sterically inhibits
both electrostatic and hydrophobic reactions with plasma
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proteins and/or cells and thereby reduces liposomal uptake by the
RES (Ishida et al., 2001a). The use of PEG significantlyminimizes,
but does not completely circumvent, liposomal uptake by the
RES—with pathways independent of opsonization also possible
(Laverman et al., 2001; Sawant and Torchilin, 2012).
Opsonins and Vesicle Destabilization
The degree of interaction between liposomal drug delivery
systems and plasma proteins is important in determining overall
nanocarrier biodistribution, efficacy, and toxicity (Hua and Wu,
2013). Plasma proteins have been shown to play a pivotal role
in liposomal clearance by the RES via opsonization, as well as
in vesicular destabilization (Cullis et al., 1998). Opsonization of
liposomes by serum proteins depends on a variety of factors
including size, surface charge and stability (Cullis et al., 1998;
Ishida et al., 2001a). The extent of this interaction has been
shown to decrease with liposome size from 800 to 200 nm in
diameter, as small liposomes cannot support opsonic activity
(Chrai et al., 2002). This profound effect of liposome size on
complement recognition can also affect liver uptake (Chrai et al.,
2002). Generally, large unmodified liposomes are eliminated
more rapidly than small, neutral, or positively charged liposomes
(Oku and Namba, 1994; Laverman et al., 1999; Ulrich, 2002).
Nevertheless, the presence of high electrostatic charge can
still promote the interaction of liposomes with biomolecules
that can serve as opsonins (Laverman et al., 1999; Ishida
et al., 2001a). Previous investigation has revealed that large,
charged liposomes are cleared within minutes by the liver and
less than an hour by the spleen (Senior, 1987; Chrai et al.,
2002). The inclusion of cholesterol is an important factor
for increasing liposome stability and minimizing phospholipid
exchange (Willis and Forssen, 1998). Incorporation of cholesterol
into the liposomal membrane abates lipid exchange with other
circulating structures (e.g., red blood cells and lipoproteins) that
can cause the depletion of high phase transition temperature
lipids and their replacement with less physiologically stable
components (Willis and Forssen, 1998; Laverman et al., 1999;
Ulrich, 2002). Integrating cholesterol into small (approximately
100 nm), electrostatically neutral liposomes has been shown to
prolong circulation time in the range of several hours (Geng et al.,
2014).
The Enhanced Permeability and Retention
(EPR) Effect
Liposomes that have evaded both the RES and opsonization are
subjected to the EPR effect (Sawant and Torchilin, 2012; Nehoff
et al., 2014). The EPR effect refers to the increased permeability
of the vasculature that supplies pathological tissues (e.g.,
tumors and conditions involving inflammation). At these sites,
deregulations in angiogenesis and/or the increased expression
and activation of vascular permeability factors predominates
(Nehoff et al., 2014), which leads to fenestrations that can range
from 300 to 4700 nm. This allows liposomes to extravasate
and accumulate by passive targeting (Hashizume et al., 2000).
For example, inflammation results in a dramatic change in
blood vessel permeability as the capillary vasculature undergoes
structural remodeling to allow leukocyte diapedesis into the
peripheral tissue (Klimuk et al., 1999; Hua, 2013). The width
of the tight junctional regions between endothelial cells in vivo
has been reported to range from 12 to 20 nm (Antohe et al.,
2004), however exposure to inflammatory mediators increases
permeability of the microvasculature, with the formation of
gaps of up to 1µm (Antohe et al., 2004). Pore sizes ranging
from 0.2 to 1.2µm have been observed, though the size and
number of pores are dependent upon the microenvironment of
the pathological site (Klimuk et al., 1999; Antohe et al., 2004;
Hua, 2013). Importantly, all types of liposomal delivery systems
are subjected to the EPR effect, with PEGylated liposomes having
an advantage due to having reduced RES clearance and extended
circulation time (Sawant and Torchilin, 2012).
The Accelerated Blood Clearance (ABC)
Phenomenon
The interaction of liposome components with the immune
system has contributed to the challenges in translation to clinical
use. Synthetic modifications to enhance their utility as drug
delivery vehicles can result in antibody production against their
various components and/or the encapsulated cargo. For example,
repeated injection of PEGylated liposomes has been associated
with loss of their long circulating properties and subsequent
clearance from the blood (Dams et al., 2000; Ishida et al.,
2003, 2006b). This phenomenon is known as the “accelerated
blood clearance” (ABC) phenomenon. The ABC phenomenon
is a major concern for the clinical application of PEGylated
formulations that require multiple dosing regimens. Dams et al.
first observed the ABC phenomenon by demonstrating that
prior dosing of empty PEGylated liposomes influences the
pharmacokinetics and biodistribution of the second dose of
liposomes in rats and rhesus monkeys, when the doses were
administered with an interval of 7 days (Dams et al., 2000). As
a result, the circulation time of the second dose of PEGylated
liposomes was significantly reduced, and liposome accumulation
in the liver and spleen increased (Dams et al., 2000). Subsequent
investigations have verified these findings, with a maximum
clearance of liposomes 4–7 days after the initial dose in rats and
10 days in mice (Ishida et al., 2003, 2006b).
The exact mechanism underlying the ABC phenomenon is
unclear. This phenomenon is affected by lipid dose, PEG surface
density, and the interval between the first and consecutive
injections (Ishida and Kiwada, 2008). Repeated injection of
empty PEGylated liposomes in rats has been shown to elicit
marked anti-PEG IgM production (Ishida et al., 2006b). This
immune response is thought to be mediated by the spleen, as the
degree of anti-PEG IgM production and the ABC phenomenon
is dramatically decreased in splenectomized rats (Ishida et al.,
2006a). Interestingly, administration of higher doses of the
initial PEGylated liposomes (>1µmol phospholipids/kg) have
been shown to reduce the magnitude of the ABC phenomenon
(Ishida et al., 2005). Increasing the phospholipid dose has been
suggested to cause PEG-reactive B cells to become apoptotic,
reducing anti-PEG IgM production and thus abating the ABC
phenomenon (Ishida et al., 2006b; Ishida and Kiwada, 2008). The
ABC phenomenon has not been reported to occur in patients
receiving PLD, even after multiple-dosing regimens (Laverman
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et al., 2001). Generally higher doses (15µmol phospholipid/kg)
are administered clinically, which may account for this absence
of the ABC phenomenon (Lyass et al., 2000). In addition, this
response may also be due to doxorubicin-mediated macrophage
death and the inhibition of B-cell proliferation and/or the death
of proliferated B-cells (Ishida et al., 2006b; Szebeni andMoghimi,
2009).
Complement Activation–Related
Pseudoallergy (CARPA)
Some liposomal systems are able to trigger the innate immune
response, with subsequent activation of the complement system
to trigger an acute hypersensitivity syndrome known as
complement activation–related pseudoallergy (CARPA). The
complement system is part of the innate immune response,
and is involved in a range of immunological and inflammatory
processes (Moghimi and Hunter, 2001). A relatively high
percentage of patients (2–45%) have been reported to develop
infusion-related hypersensitivity reactions to liposomal drug
therapy. In addition, CARPA has been reported with both
experimental and clinically approved liposomal formulations
(e.g., Doxil R©, Ambisome, and DaunoXome R©) (Szebeni, 2005;
Szebeni and Moghimi, 2009). CARPA is an immediate, non-IgE-
mediated hypersensitivity reaction that involves symptoms such
as anaphylaxis, facial flushing, facial swelling, headache, chills,
and cardiopulmonary distress (Szebeni, 2005—the latter of which
may limit the clinical use of potentially reactogenic liposomes
in cardiac patients (Szebeni and Barenholz, 2009). General
clinical management involves slowing the infusion rate or ceasing
therapy, as well as the use of standard allergy medications (e.g.,
antihistamines, epinephrine, and corticosteroids).
This pseudoallergy is thought to be partly due to the
activation of the complement system with the subsequent
generation of C3 split-products (e.g., C3d) (Dempsey et al.,
1996) and anaphylatoxins C3a and C5a (Szebeni, 2005; Szebeni
and Moghimi, 2009). Binding of anaphylatoxins to their specific
receptors on immune cells (e.g., mast cells, basophils, and
macrophages) elicits the release of a multitude of vasoactive
mediators, including histamine, tryptase, platelet-activating
factor (PAF), leukotrienes (e.g., LTB2, LTB4, LTC4, LTD4, LTE4),
thromboxane A2 (TXA2), and prostaglandins (e.g., PGD2).
Initial activation triggers include the binding of IgG, IgM,
C reactive protein (CRP), C1q, C3, and potentially, mannose
binding lectin (MBL) and ficolin, to the liposomal vesicles
(Szebeni and Barenholz, 2009). It should be noted that the
sensitivity of different species to liposomal CARPA shows
substantial variation, with some species (dogs and pigs) also
showing tachyphylaxis (tolerance induction) following additional
doses (Szebeni et al., 1999, 2007). Therefore, desensitization
protocols using empty liposomesmay be used to prevent CARPA,
as well as pre-administration of complement inhibitors (e.g.,
soluble C receptor type 1, anti-C5 antibody, and indomethacin)
(Szebeni and Barenholz, 2009).
All types of liposomes can activate the complement system.
Liposome size, morphology, charge, lipid composition, bilayer
packaging, surface characteristics, and administered lipid dose all
regulate complement activation (Szebeni and Moghimi, 2009).
Specific liposomal characteristics that enhance the propensity
for complement activation include a positive or negative
surface charge, increasing size, lack of liposomal homogeneity,
endotoxin contamination, presence of aggregates, presence of
drugs that can bind to and aggregate liposomes/lipids, presence
of cholesterol in the bilayer membrane at≥70%, and PEGylation
with PEG-PE (Szebeni and Barenholz, 2009). Based on these
findings, neutral small unilamellar vesicles have been shown
to be the least reactogenic of the liposomal platforms (Szebeni
and Barenholz, 2009). Formulation strategies to minimize the
immunogenicity of liposomes have included methylation of the
anionic charge localized on the phosphate oxygen of mPEG-
phospholipid conjugate (Moghimi et al., 2006) or the use of other
non-ionic lipopolymers and lipid conjugates, such as mPEG-
substituted synthetic ceramides (Webb et al., 1998; Szebeni and
Moghimi, 2009). The development of immunogenic reactions
to liposomal therapies may lead to altered pharmacokinetics,
loss of efficacy, and the rise of potentially serious toxicities (e.g.,
anaphylaxis) (Szebeni andMoghimi, 2009). This should therefore
be considered in formulation design and closely monitored for in
clinical practice.
EXPERIMENTAL USE OF LIPOSOMES FOR
BIOMEDICAL APPLICATIONS
The application of liposomes in medicine offers significant
prospects for novel and effective treatments in a wide range of
pathological conditions. Since the discovery of liposomes over
50 years ago, there has been a significant increase in lipid–
based drug delivery research at the experimental in vitro and
in vivo phase. Liposomes have been utilized as a drug delivery
carrier for a wide range of therapeutic compounds and diagnostic
agents, such as drug molecules, gene therapy and bioactive agents
(Hua and Wu, 2013). Modifications of these formulations are
constantly being investigated in an effort to improve efficacy,
reduce RES clearance and minimize toxicity—this includes
changes in lipid composition, charge, and the addition of surface
coatings and ligands (Hua and Wu, 2013; Monteiro et al.,
2014). More recent strategies to improve on conventional or
stealth liposomal systems involve active targeting, charged lipids,
triggered release, and multi-functional formulations (Puri et al.,
2009; Allen and Cullis, 2013; Bozzuto and Molinari, 2015).
Active targeting approaches with the conjugation of targeting
ligands to the surface of liposomes have been extensively studied
at the experimental level for a variety of biomedical applications,
and particularly following parenteral administration (e.g.,
intravenous and intraperitoneal injection) (Torchilin, 1994;
Vingerhoeds et al., 1994; Willis and Forssen, 1998; Noble
et al., 2004; Deshpande et al., 2013; Hua and Cabot, 2013;
Rip et al., 2014; Hua et al., 2015). Targeting ligands are
used to increase the specificity of delivery of encapsulated
cargo to and retain it in diseased tissues and cells, with
minimal deposition in non-target sites. The notion that ligand-
targeted liposomes have a therapeutic advantage over non-
targeted liposomes is still subject to debate, with conflicting
results in the literature (Ferrari, 2005; Puri et al., 2009;
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Riehemann et al., 2009). A number of studies have demonstrated
enhanced uptake and efficacy of ligand-targeted liposomes in
diseased tissue in comparison to non-targeted liposomes in
vivo (Vingerhoeds et al., 1994; Puri et al., 2009; Allen and
Cullis, 2013; Kraft et al., 2014). For example, attachment
of folate to liposomes showed enhanced biodistribution of
liposomes in folate-expressing tumors in a murine model
(Gabizon et al., 2003). In addition, attachment of ICAM-1
monoclonal antibodies to the surface of loperamide-encapsulated
liposomes, demonstrated increased efficacy and localization of
the targeted nanoparticles to peripheral inflammatory tissue in
a rodent model of musculoskeletal pain (Hua and Cabot, 2013).
Conversely, there are studies that have shown no difference in
the biodistribution and target tissue accumulation of ligand-
targeted liposomes compared with non-targeted liposomes. For
example, conjugation of HER2 monoclonal antibody fragments
to liposomes did not increase the tumor localization of the
nanoparticles, with both targeted and non-targeted liposomes
achieving similarly high levels of tumor tissue accumulation
(7–8% injected dose/g tumor tissue) in HER2-overexpressing
breast cancer xenografts models (Kirpotin et al., 1997, 2006).
However, doxorubicin-loaded anti-HER2 immunoliposomes
produced significantly superior therapeutic results in comparison
to all other control groups, including free doxorubicin, non-
targeted liposomal doxorubicin and recombinant anti-HER2
Mab trastuzumab (Park et al., 2002). The mechanism of this
enhanced anti-tumor efficacy was clearly not due to enhanced
accumulation via antigen binding, but rather the result of
the marked difference in pharmacodynamics of the targeted
liposomal formulation in vivo, by mediating intracellular drug
delivery to HER2-overexpressing cancer cells (Kirpotin et al.,
2006). Therefore, it is likely that attachment of targeting
moieties enhances therapeutic efficacy by increasing receptor-
mediated uptake of drug-encapsulated liposomes into target
cells, subsequent to the accumulation of the nanocarriers in the
diseased tissues (Kirpotin et al., 2006; Puri et al., 2009).
Despite the improved biodistribution and therapeutic
outcomes of ligand-targeted liposomes in a number of preclinical
studies, the advantages have so far been negligible in the clinical
research phase. Possible reasons for this discrepancy have
previously been reviewed (Sawant and Torchilin, 2012; Allen
and Cullis, 2013), and include factors such as disease-dependent
anatomical and physiological barriers, target accessibility and
expression, and formulation stability. The optimal targeting
ligand density on the surface of each liposome still remains
to be resolved, and will likely depend on characteristics of the
molecular target (e.g., location, expression, internalization rate,
and immunogenicity) (Puri et al., 2009; Hua and Wu, 2013;
Kraft et al., 2014). In addition, detailed analysis of the degree
of liposome accumulation, cellular internalization, intracellular
functionality and intracellular degradation will be important
parameters for clinical validation and translation (Puri et al.,
2009). Through extensive experimentation, we are gaining a
better understanding of the more appropriate clinical indications
for ligand-targeted liposomal formulations.
Furthermore, modifications of the lipid bilayer with charged
lipids have also attracted much attention (Bozzuto and Molinari,
2015). Addition of charged lipids to the liposomal bilayer
has played an important role in developing bioadhesive,
mucoadhesive and nucleic acid-based delivery systems. For
example, modifying the surface charge of nano-delivery systems
can influence the electrostatic interaction of the nanocarriers
with components in the gastrointestinal (GI) tract following
oral administration, and theoretically should confer selectivity
to diseased tissue (Hua et al., 2015). Cationic nano-delivery
systems have been shown to adhere to the mucosal surface
within inflamed GI tissue, due to the interaction between
the positively charged nanocarrier and the negatively charged
intestinal mucosa (Coco et al., 2013). Colonic mucins carry a
negative charge since their carbohydrates are substituted with
numerous sulfate and sialic acid residues (Larsson et al., 2009;
Antoni et al., 2014). Conversely, anionic nano-delivery systems
preferentially adhere to inflamed GI tissue via electrostatic
interaction with the higher concentration of positively charged
proteins in inflamed regions. In particular, high amounts of
eosinophil cationic protein and transferrin have been observed
in inflamed colon sections in patients with inflammatory bowel
disease (IBD) (Carlson et al., 1999; Peterson et al., 2002; Tirosh
et al., 2009). Cationic nano-delivery systems are also able to
effectively transport large, charged structures, such as DNA and
RNA, based on electrostatic interaction between the positively
charged phospholipids [e.g., dioleoylphosphatidylethanolamine
(DOPE)] and negatively charged nucleic acids (Felgner et al.,
1987; Campbell et al., 2002, 2009; Kunstfeld et al., 2003; Wu
et al., 2007). Such liposomes have also been demonstrated to have
greater interaction with tumor vessels due to the overexpression
of negatively charged functional groups on the angiogenic
endothelial cell membrane (Ran et al., 2002). It should be noted
however, that there is a potential for electrostatic interactions
and subsequent binding of these charged nanoparticles with
other charge-modifying substances in the circulation or during
GI transit (Hua et al., 2015). In addition, recent studies have
identified potentially toxic in vitro and in vivo effects with the
use of cationic lipids and polymers, including cell shrinking,
reduced number of mitoses, vacuolization of the cytoplasm, and
detrimental effects on key cellular proteins (e.g., protein kinase
C) (Lv et al., 2006). For cationic lipids, the cytotoxic effects
are determined by the structure of its hydrophilic group, with
quaternary ammonium amphiphiles being more toxic than their
tertiary amine counterparts. Inclusion of a heterocyclic ring has
been shown to spread the positive charge of the head-group, thus
attenuating the toxicity level (Lv et al., 2006).
Another approach to improve therapeutic efficacy of
liposomal formulations has been to use triggering modalities
for site-specific release of therapeutics from liposomes (Bibi
et al., 2012). Strategies that have been utilized include remote
triggers (e.g., temperature, ultrasound, magnetic, and light) and
local triggers specific to the target site (e.g., enzymes and pH),
through the use of specific lipid compositions and coatings
(Guo and Szoka, 2003; Andresen et al., 2004; Ponce et al., 2006;
Bibi et al., 2012). Of these strategies, the use of an external
hyperthermic trigger to release therapeutic compounds from
liposomal formulations (e.g., ThermoDox R©) appears to be the
most promising to date (Needham et al., 2000). Thermosensitive
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liposomes are modified with temperature-sensitive lipids (e.g.,
1,2-distearoyl-sn-glycero-3-phosphocholine, DSPC) and/or
polymers [e.g., poly(N-isopropylacrylamide)], which enables
the nanocarrier to remain stable and retain their contents
at physiologic temperatures. Upon heating, these liposomes
undergo a phase change that makes them more permeable,
causing the release of their cargo (Kono, 2001). Recent studies
have investigated the use of cationic thermosensitive liposomes
(CTSL) for tumor targeting (Dicheva et al., 2013, 2014),
with promising results showing doxorubicin-encapsulated
CTSLs having three-fold higher accumulation at the target
site compared to the thermosensitive liposomal formulation
(Dicheva et al., 2014). Translation of these drug delivery
systems into the clinic has not yet been successful, with issues
surrounding therapeutic efficacy (e.g., location of diseased tissue
and accessibility for remote triggers) and potential toxicity of
particularly synthetic components of the drug delivery system
(Bibi et al., 2012; Allen and Cullis, 2013). Overall, this technology
is promising and does warrant further investigation to determine
which disease states would benefit from this localized treatment
platform and how to make such formulations safer for clinical
use.
Finally, a number of experimental studies have focussed on
complex multi-functional liposomal formulations in an attempt
to develop more efficient drug delivery systems. These include
liposomal formulations that combine one or more of the
following strategies—active targeting with one or more targeting
ligands, response to triggers to control drug release, delivery of
a combination of therapeutics (e.g., siRNA and small molecule
drugs), and biomarker and imaging capabilities (Zhang et al.,
2011; Allen and Cullis, 2013; Charron et al., 2015; Cole and
Holland, 2015). In particular, theranostic nanoparticles have
generated much interest as it is both a therapeutic and diagnostic
tool all-in-one (Figure 1). A typical theranostic delivery system
would include the nanoparticle, imaging component, targeting
ligand, and therapeutic agent. A number of studies have
shown effective diagnostic imaging and therapeutic delivery
of encapsulated drugs in vivo with theranostic nanosystems,
especially in various cancers (Charron et al., 2015; Cole and
Holland, 2015). For example, Han et al. (2014) conjugated ECl-
GLuc to nickel-chelating liposomes (ECl-GLuc-liposome), and
demonstrated significant bioluminescence imaging and targeted
drug delivery in both SKOv3 cells in vitro and in ErbB2-
overexpressing metastatic ovarian tumors in vivo in a murine
model (Han et al., 2014). ECl-GLuc is a recombinant protein
generated by fusing the ECl peptide (an artificial ligand of
ErbB2) with Gaussia luciferase (GLuc). Although innovative and
efficient, translation of multi-functional drug delivery systems to
the clinic would need to show significant therapeutic advantage
over other therapeutic strategies, due to the added costs and
complexities required in the manufacturing process. In addition,
multi-functional systems will need to address the potential
mismatch between the doses required for the effective use of
each component in patients, for example imaging and therapy
for theranostic nanosystems (Teli et al., 2010). At this stage,
packaging multiple payloads in the same carrier would appear
most promising, however sequencing and scale up of this kind
of approach would still be challenging (Zhang et al., 2011; Allen
and Cullis, 2013).
CLINICALLY APPROVED
LIPOSOMAL-BASED THERAPEUTICS
Many liposomal products are on the market with more in
clinical development. Some of the most successful delivery
methods rely on PEG conjugated lipids. In fact, the first FDA
approved nano-drug, doxorubicin, is delivered using PEGylated
liposomes (Ning et al., 2007). Often used in combination with
other medicines, PLD treats various types of cancer including
AIDS-related Kaposi’s sarcoma, leukemia, and ovarian, breast,
bone, lung, and brain cancers. PLD has also been found to be
an effective alternative to conventional doxorubicin in patients
with pre-existing cardiac dysfunction (Schmitt et al., 2012).
When doxorubicin is incorporated in PEGylated liposomes,
it minimizes the uptake and clearance by the RES, which
prolongs the serum and plasma half-life. This allows the PLD
to accumulate in the tumor tissue, rather than in non-target
healthy tissues (Rahman et al., 2007). Furthermore, the use of
PLD ensures that doxorubicin can pass through the myocardium
without being released and contributing to cardiac muscle cell
toxicity (Rahman et al., 2007). Finally, PLD avoids the high
plasma peak levels of free drug, which has been correlated with
cardiotoxicity (Lyass et al., 2000). In addition to receiving FDA
approval for usage of PLD in 1995, combination therapies of PLD
and other drugs (such as bortezomib for the treatment of relapsed
or refractory multiple myeloma) have recently received FDA
approval (Ning et al., 2007). Another type of PEGylated liposome
currently in Phase I trials is PEPO2, an irinotecan-encapsulated
liposomal formulation used to treat advanced refractory solid
tumors (Chang et al., 2015). Camptothecin, which is formulated
in PEGylated stealth liposomes, is also in Phase I trials for ovarian
cancer treatment (Zamboni et al., 2009).
In addition to PEG conjugated lipids, conventional and
cationic liposomal-based drugs have also been FDA approved.
Liposomal amphotericin B for anti-fungal prophylaxis
(Chandrasekar, 2008), daunorubicin for the treatment of
leukemia and solid tumors (Chang and Yeh, 2012), verteporfin
to treat macular degeneration (Chang and Yeh, 2012), cytarabine
or cytosine arabinoside to treat neoplastic meningitis and
lymphomatous meningitis (Chang and Yeh, 2012; Jahn et al.,
2015), and morphine sulfate for pain management are currently
on the market (Chang and Yeh, 2012). Regardless, many of
these drugs are still undergoing clinical trials to test their
effects of dose escalation and therapeutic efficacy (Chang and
Yeh, 2012). For example, liposomal amphotericin B is in a
prospective Phase II trial to test the safety and tolerability of
high doses (Giannella et al., 2015). Advantages of these marketed
drugs include a reduced toxicity by increased vasculature
permeability/accumulation at the target tissue and an ability to
encapsulate drugs of different lipophilicities while protecting
them from biodegradation (Immordino et al., 2006; Chang and
Yeh, 2012; Allen and Cullis, 2013).
Many more liposomal-based drugs are in various stages
of clinical development to test their pharmacokinetics and
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biodistribution profiles. These include irinotecan SN-38 in Phase
I/II to treat colorectal cancer (Zhang et al., 2004; Suenaga
et al., 2015) and a liposomal-based all-trans-retinoic acid (ATRA)
in Phase II that contains the drug tretinoin to treat acute
promyelocytic leukemia and hormone-refractory prostate cancer
(Ozpolat et al., 2003). One type of conventional liposomal
formation is EndoTAG-1, which carries paclitaxel. It is embedded
in a cationic liposome and is in Phase II trials to treat
advanced triple-negative breast cancer (Awada et al., 2014) and
pancreatic cancer (Löhr et al., 2012). EndoTAG-1 is prepared
in a 50:47:3 molar ratio of 1,2-dioleoyl-3-trimethylammonium
propane (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), and paclitaxel (Chang and Yeh, 2012). EndoTAG-1
exhibits a greater antivascular effect on tumor vasculature while
the usage of DOTAP, a cationic synthetic lipid, in EndoTAG-
1 allows for selective affinity to the target tumor (Chang and
Yeh, 2012). Another form of paclitaxel, LEP-ETU (liposome-
entrapped paclitaxel easy-to-use), is in Phase I/II trials (Zhang
et al., 2005; Immordino et al., 2006). LEP-ETU is prepared
in a 90:5:5 molar ratio of DOPC, cholesterol, and cardiolipin
(Chang and Yeh, 2012). Higher doses of LEP-ET can be safely
administered compared to paclitaxel alone (Fetterly et al., 2008).
Additionally, the use of cholesterol and cardiolipin allows for
greater stability and reduced cardiotoxicity, respectively (Chang
and Yeh, 2012). DOPC is a recently developed neutral liposome
carrier for siRNA delivery and is currently in clinical testing
(Mangala et al., 2009). Another drug in Phase I/II trials is
annamycin to treat acute lymphocytic leukemia (Wetzler et al.,
2013). With non-cross resistance properties and an enhanced
cellular uptake and retention, annamycin’s efficacy and anti-
tumor activity is enhanced with the use of a targeted liposomal-
based delivery system (Zou et al., 1994). These and more
liposomal-based drugs that are FDA approved or currently in
clinical trials are summarized in Table 1.
WHY THE BOTTLENECK FOR
TRANSLATION INTO CLINICAL
PRACTICE?
Despite considerable research in the last 50 years, the clinical
translation of liposome assisted drug delivery platforms has not
progressed as quickly as the plethora of positive results would
have suggested. Liposomal formulations have demonstrated
significant therapeutic advantages for a multitude of biomedical
applications, however the major reasons for the bottleneck
have been attributed to issues surrounding pharmaceutical
manufacturing, government regulations and intellectual property
(IP). Similar obstacles are faced by other nano-delivery systems
for translation into the clinic (Allen and Cullis, 2004, 2013;
Zhang et al., 2008; Sawant and Torchilin, 2012; Narang et al.,
2013). Limitations in pharmaceutical development are centered
on quality assurance and cost. Quality assurance involves issues
surrounding the manufacturing process and stability of the
formulation, with nano-delivery systems being affected by (i)
scalability of the manufacturing process, (ii) reliability and
reproducibility of the final product, (iii) lack of equipment and/or
in-house expertise, (iv) chemical instability or denaturation of the
encapsulated compound in the manufacturing process, and (v)
long term stability issues (Narang et al., 2013). Suitable methods
for the industrial scale production of conventional liposomes
have been successfully developed, without the need for numerous
manufacturing steps or the use of organic solvents (Jaafar-Maalej
et al., 2012; Kraft et al., 2014). The challenges arise when the
functionality of the liposomal delivery system becomes more
complex, such as the addition of surface modification with
coatings and/or ligands. Integration of multiple components to
a single nanosized carrier requires multiple chemical synthesis
steps and formulation processes, which inevitably pose problems
for large scale goodmanufacturing (cGMP) production, increases
the cost of production, and makes the evaluation of such
products more difficult (Teli et al., 2010; Tinkle et al., 2014).
Increasing the number of physicochemical variables in a
nanoformulation system also makes it more complicated to
assess the pharmacokinetics, pharmacodynamics and toxicology
of a formulation following administration (Teli et al., 2010;
Tinkle et al., 2014). For example, the use of synthetic coatings
and ligands may affect the biocompatibility, biodistribution
and toxicology profile of liposomal formulations, and will
require further evaluation to understand the interaction of the
nanoparticles with biological tissues and cells (Allen and Cullis,
2004, 2013; Zhang et al., 2008; Sawant and Torchilin, 2012;
Narang et al., 2013; Tinkle et al., 2014). Improvements in the
regulatory framework for the assessment of nanoformulations
will require consultation with academia and industry.
IP of liposomal based therapies can be a perplexing issue
and is likely to contribute to increasing development costs.
IP strategies may vary depending on various factors including
non-targeted or targeted liposomal formulations, the design
and composition of the liposomes, and drugs that may be
encapsulated. Any of these factors may contribute to a weak
IP position and reduce the commercial attractiveness of the
formulation—this will have implications on further development
of the product in the research and development pipeline.
Given the complexities of incorporating nanotechnology into
biomedical applications, there will likely be multiple patents
associated with any given technology and the need for cross-
licensing arrangements (Murday et al., 2009). It will be important
to simplify the pathway from invention to commercialization
through new IP practices and protocols, so as to reduce the time
and expense required for negotiating collaboration and licensing
agreements (Murday et al., 2009).
Finally, clinical trials of liposomal formulations are generally
more complex than conventional formulations, as a number
of control groups are required to account for different aspects
of the drug delivery system. In order to get to this stage, the
formulation has to first pass pharmaceutical and commercial
qualities as discussed above. Then we can determine whether
therapeutic efficacy in preclinical animal studies translate to
success in humans (Allen and Cullis, 2004, 2013; Narang et al.,
2013). Even at this stage, the cost-benefit analysis may be a
limitation to the clinical translation of some liposomal based
therapies when compared to an approved counterpart or existing
therapies, in terms of efficacy or drug-related side effects.
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TABLE 1 | Marketed liposomal-based therapeutics and products in clinical development.
Drug Disease Status Type of liposomal-based Source(s)
delivery system
Paclitaxel LEP-ETU Advanced triple-negative breast cancer Phase I/II siRNA Zhang et al., 2005; Immordino
et al., 2006
siRNA Ovarian cancer Phase I DOPC neutral liposomes Mangala et al., 2009
Paclitaxel EndoTAG-1 Advanced triple-negative breast cancer Phase II Cationic Chang and Yeh, 2012; Awada
et al., 2014
Paclitaxel EndoTAG-1 Pancreatic cancer Phase II Cationic Löhr et al., 2012
Mitoxantrone LEM-ETU Acute myeloid leukemia, multiple sclerosis,
and prostate cancer
Phase I Cationic Immordino et al., 2006; Chang
and Yeh, 2012
Verteporfin Molecular degeneration FDA Approved in 2000 Cationic Chang and Yeh, 2012; Allen and
Cullis, 2013; Gross et al., 2013
Amikacin Lung infection Phase II/III Conventional Chang and Yeh, 2012; Clancy
et al., 2013; Olivier et al., 2014
Vincristine Non-Hodgkin lymphoma FDA Approved in 2012 Conventional Allen and Cullis, 2013; Wang
et al., 2015
Tretinoin Acute promyelocytic leukemia and
hormone-refractory prostate cancer
Phase II Conventional Ozpolat et al., 2003; Immordino
et al., 2006
Irinotecan SN-38 Metastatic colorectal cancer Phase I/II Conventional Zhang et al., 2004; Suenaga
et al., 2015
Annamycin Acute lymphoblastic leukemia Phase I/II Conventional Wetzler et al., 2013
Amphotericin B Anti-fungal prophylaxis FDA approved in 1997 Conventional Chandrasekar, 2008; Allen and
Cullis, 2013
Daunorubicin Leukemia and solid tumors FDA Approved in 1996 Conventional Chang and Yeh, 2012; Allen and
Cullis, 2013
Cytarabine or cytosine
arabinoside
Neoplastic meningitis and lymphomatous
meningitis
FDA Approved Conventional Chang and Yeh, 2012; Jahn
et al., 2015
Morphine sulfate Pain Management FDA Approved in 2004 Conventional Chang and Yeh, 2012; Allen and
Cullis, 2013
Lurtotecan Ovarian cancer, head, and neck cancer Phase I/II Conventional Dark et al., 2005; Chang and
Yeh, 2012
Vinorelbine Newly diagnosed or relapsed solid tumors Phase I Conventional Allen and Cullis, 2013
Topotecan Advanced solid tumors Phase 1/II Conventional Seiden et al., 2004; Allen and
Cullis, 2013
Nystatin Fungal Infections Phase I/II Conventional Offner et al., 2004
Doxorubicin Leukemia, breast cancer, bone cancer,
lung cancer, brain cancer
FDA Approved in 1995 PEGylated Ning et al., 2007
Doxorubicin and bortezomib Relapsed or refractory multiple myeloma FDA Approved in 2007 PEGylated Ning et al., 2007
Thermosensitive doxorubicin Liver tumors Phase III PEGylated Yarmolenko et al., 2010
Thermosensitive doxorubicin Chest wall recurrences of breast cancer Phase I PEGylated Yarmolenko et al., 2010
Irinotecan Advanced refractory solid tumors and
colorectal cancer
Phase I PEGylated Chang et al., 2015
Camptothecin analog Ovarian cancer Phase I PEGylated Zamboni et al., 2009
CONCLUSION
The application of liposomes to assist drug delivery has already
had a major impact on many biomedical areas. Understanding
the advances in liposomal technology to date and the challenges
that still need to be overcome, will allow future research to
improve on existing platforms and to address the current
translational and regulatory limitations. Continued translational
success will require communication and collaboration between
experts involved in all stages of pharmaceutical development
of liposomal technologies, including manufacturing and
pharmaceutical design, cellular interactions and toxicology, as
well as preclinical and clinical evaluation.
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